74 results about "Differentiation Inducer" patented technology

Disclosed are preparations of placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.

Methods and compositions are disclosed for inducing differentiation and apoptosis in cells that overexpress Notch proteins. A cell fate determining function of Notch is specifically disrupted at a time when the cell is undergoing differentiation, which causes the cell to undergo apoptosis. The invention includes therapies for tumors that overexpress a Notch protein (such as Notch-1) by inducing differentiation of the cells in the tumor with a differentiation inducing agent, such as HMBA, in combination with an agent that disrupts the function of the Notch protein. At a time during which differentiation has been promoted, and the cell is susceptible to interference with the anti-apoptosis effect of Notch, the function of the Notch protein is disrupted. Disruption of Notch function can be achieved, for example, by a differentiation inducing agent, such as HMBA, combined with antibodies that specifically bind to Notch and inactivate it, for example a monoclonal antibody that recognizes Notch-1 EGF-like repeats 11 and 12, such as monoclonal antibodies A6, C11 or F3. Disruption of Notch function can also be achieved by the expression of antisense oligonucleotides that specifically interfere with expression of the Notch protein on the cell, alone or in combination with antineoplastic agents.

The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.

There is provided a method of inducing bone marrow stromal cells to differentiate into bone marrow stromal cell-derived Schwann cells in vitro, comprising the steps of: collecting bone marrow stromal cells from bone marrow and culturing the cells in a standard essential culture medium supplemented with a serum; adding a reducing agent to the culture medium and further culturing the cells; adding a differentiation inducing agent to the culture medium and further culturing the cells; and adding a cyclic AMP-augmenting agent or a cyclic AMP analogue and / or a glial cell differentiation and survival stimulating factor to the culture medium, and further culturing the cells to obtain the bone marrow stromal cell-derived Schwann cells. There are also provided bone marrow stromal cell-derived Schwann cells obtained thereby and a pharmaceutical composition for neural regeneration that comprises them.

The invention provides an inducing method and inducing culture medium for differentiation of bone marrow mesenchymal stem cells into osteoblasts in vitro. The inducing culture medium is composed of 1*10<-8> mol / L of dexamethasone, 50 mu mol / L of ascorbic acid and 10 mmol / L of sodium beta-glycerophosphate; and solvent is a supernatant of a sclerite complete culture medium and comprises 10% of fetal calf serum, 100 U / mL of penicillin, 100 mg / L of streptomycin, a mixture of DMEM culture fluid and F12 culture fluid and multiple growth factors secreted by bone cells in the sclerite culture process. According to the invention, bone marrow mesenchymal stem cells of a mouse are purified by replacing the cell culture fluid through an adherent cell passage method, the obtained cells of the first generation are induced, and the supernatant of the sclerite complete culture medium cultured for 72-96 hours is used as the solvent of osteoblast differentiation inducer, thereby obviously improving the in vitro osteogenic differentiation efficiency of bone marrow mesenchymal stem cells.

The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.

Disclosed is a method for culturing myocardium-resident cardiac progenitor cells, comprising: embedding myocardial fragments into hydrogel; culturing the myocardial fragment into hydrogel; degrading only the hydrogel to recover cardiac progenitor cells grown out of the myocardial fragment to the hydrogel; and amplifying the cardiac progenitor cells in vitro. Also, the cardiac progenitor cells, a method for differentiating the same, and the use thereof as cell therapeutic agent for heart diseases are provided. In addition to possessing the potential to differentiate into cardiomyocytes, osteoblasts, adipocytes, chondrocytes, vascular endothelial cells, smooth muscle cells, neural cells, and skeletal muscle cells, the myocardium-resident cardiac progenitor cells can spontaneously differentiate into cardiomyocytes even in the absence of a special differentiation inducing agent. Thus, the cardiac progenitor cells can be used to produce bio-active medicines such as cell therapeutics and tissue engineering therapeutics with high industrial applicability.

The invention relates to a method of inducing and differentiating human umbilical cord derived mesenchymal stem cells into cartilage cells. The method includes: in order to solve the problem that the prior art is low in differentiation efficiency, cleaning umbilical cord tissue to remove blood stain, cutting the same into small sections, dissecting the small sections to remove vascular tissue, cutting the small sections into pieces, and digesting to obtain a single mesenchymal stem cell; culturing the obtained mesenchymal stem cell in an amplification manner to the seventh generation to obtain a unicellular suspension, inoculating the unicellular suspension into a serum-free culture medium containing a cartilage differentiation inducer to continue culturing, replacing a fresh culture medium every other 3.5 days, and inducing for 14 days to obtain the cartilage cells. The method can efficiently differentiate the umbilical cord mesenchymal stem cells into the cartilage cells and is of important significance in the aspects of restoring cartilage tissue in human bodies and treating bone injury.

The invention belongs to the technical field of cell induced differentiation, and in particular relates to an inducing agent and a culture medium for directional differentiation of an adipose-derived stem cell. The inducing agent for transformation of an adipose-derived stem cell into a testosterone cell consists of icariin, retinoic acid and human chorionic gonadotropin. The inducing culture medium for transformation of the adipose-derived stem cell into the testosterone cell is prepared by a method as follows: each 1000ml of the inducing culture medium consists of 0.5-10umol of icariin, 1-10umol of retinoic acid and 20,000-80,000 units of human chorionic gonadotropin, as well as a human mesenchymal stem cell serum-free medium, and the culture medium is obtained through uniformly mixing, filtering and sterilizing. The inducing agent and the culture medium for transformation of the adipose-derived stem cell into the testosterone cell disclosed by the invention are free from cell transfection, so as to avoid risks of gene modification and cancer, and induced differentiation efficiency is high; the inducing agent and the culture medium develop characteristics of traditional Chinese medicine, and are capable of inducing transformation of the autologous adipose-derived stem cell into the testosterone cell, and are free from an ethics problem and high in safety.

The present invention relates to new use of natural medicine, and is the new use of natural abscisic acid in tumor treating medicine, and especially the new use of natural abscisic acid in preparing tumor cell differentiation inducing agent. Natural abscisic acid in the concentration of 1 microgram / L to g / L can inhibit the proliferation of tumor cell and induce the transformation of tumor cell to normal cell effectively. The present invention has the advantages of simple operation, high effect, less toxic side effect, etc.

The present invention provides a method for producing mesenchymal cells for production of mesenchymal cells for formation of a tooth, the method comprising: culturing totipotent stem cells in the presence of a differentiation inducer to produce a cell population after differentiation induction treatment, the cell population containing CD44-positive and CD29-positive cells or CD44-positive and CD 106-positive cells; and selecting, from the cell population after the differentiation induction treatment, the CD44-positive and CD29-positive cells or CD44-positive and CD 106-positive cells as the mesenchymal cells for the formation of the tooth. The present invention also provides a method for producing a tooth comprising: positioning, in a support carrier capable of retaining cells in a state of contacting therewith, a first cell mass substantially consisting of only either one of mesenchymal cells and epithelial cells and a second cell mass substantially consisting of only the other one of the mesenchymal cells and epithelial cells, the first and second cell masses being not mixed with each other but made to closely contact with each other; and culturing the first and second cell masses; wherein the mesenchymal cells comprise the mesenchymal cells for the formation of the tooth.

The invention relates to an induction method for promoting differentiation of human umbilical cord mesenchymal stem cells into chondrocytes, which comprises the following steps of: obtaining an umbilical cord tissue block, a primary culturing stem cells, subculturingstem cells and inducing stem cells differentiate to chondrocytes, wherein the induction for differentiation of stem cellsinto chondrocytes comprises the following steps of: resuspending human umbilical cord mesenchymal stem cells subcultured to a seventh generation by adopting a serum-free culture medium to prepare P7 generation stem cell suspension; inoculating P7 generation stem cell suspension into the serum-free culture medium containing a cartilage differentiation inducer for continuous culture; replacing the serum-free culture medium containing the cartilage differentiation inducer in a half amount every three days; obtaining chondrocytes after 14 days.The induction method can differentiate human umbilical cord mesenchymal stem cells into chondrocytes,which has important significance in repairing human cartilage tissues and treating bone injuries.

The invention relates to the use of certain PDE4 inhibitors alone or in combination with one or more differentiation inducing agents and / or an agent effective in raising intracellular concentrations of cAMP or a stable analogue of cAMP in the preparation of pharmaceutical compositions for the treatment of neoplasms of lymphoid cells.

Disclosed are methods of preparing and using placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.

The invention provides a novel composition or health food which has good pharmacological activity and is easily absorbed by the digestive tract. The composition contains Agaricus Agaricus extract and has the activity of inducing cell apoptosis. The composition may further comprise a pharmaceutically acceptable carrier. Typically, the cells are cancer cells. The composition further comprises a differentiation inducer. Preferably, the differentiation-inducing agent is a vitamin A derivative. The vitamin A derivative may be tretinoin. The above-mentioned Agaricus mushroom extract may comprise a main chromatographically eluted fraction having a molecular weight of 100 to 2000, which is obtained by extracting Agaricus mushroom fruiting bodies with hot water, dialyzing the obtained extract and treating the external dialysate by chromatography.

The purpose is to select low-molecular-weight compounds which are effective in inducing differentiation of mesenchymal stem cell into hepatocyte and to develop a safe differentiation-inducing method having excellent efficiency of differentiating mesenchymal stem cell into hepatocyte. Provided are at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; a differentiation inducer comprising at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; and a differentiation inducer comprising a compound represented by formula (8), a salt thereof, or a solvate of them.

The invention discloses application of a water-soluble realgar solid dispersoid in preparation of a bone marrow hematopoietic stem / progenitor cell erythroid differentiation inducer. The realgar soliddispersoid is prpeared from the following raw materials in parts by weight: 1 part of realgar, 1 to 20 parts of macromolecule and 0 to 5 parts of surfactant. According to the application disclosed bythe invention, the situation that the water-soluble realgar solid dispersoid can induce bone marrow hematopoietic stem cells / progenitor cells to differentiate toward erythrocytes is found, so that accumulation of erythroid cell in bone marrow cells is promoted, and the reduction of the quantity of the erythrocytes caused by the bone marrow hematopoietic stem / progenitor cell erythroid differentiation is effectively alleviated, anemia caused by hematopoietic obstacle is improved, and simultaneously, the bone marrow cells can be protected from being killed by medicines.

The invention belongs to the technical field of medicines, and discloses application of isoliquiritigenin to prepare medicaments of inducing a tumor to be differentiated. Tests prove that when the concentration of the isoliquiritigenin is low, the isoliquiritigenin cannot kill the tumor cells, but has the action of reversing the tumor cells in leukemia, liver cancer, malignant melanoma and the like into the cell with normal functions. Based on the characteristics, the isoliquiritigenin is mixed with other medical auxiliary materials to prepare an oral or injectable preparation; when the oral or the injectable preparation is clinically used for treating various malignant tumors, the preparation has the advantages of confirmed curative effect, no obvious toxic and side effects, and the suitability for long-period and continuous medicine-taking; and the medicament prepared by the isoliquiritigenin is obviously better than the prior medicament clinically used for treating the tumors,.

The present invention provides a nerve cell differentiation inducing drug containing a Synoviolin expression inhibitor which is a useful drug for treatments of neural disorders, particularly Alzheimer's disease, Parkinson's disease, peripheral nerve disorders or spinal injury. As Synoviolin expression inhibitors, there are siRNA against gene coding Synoviolin (SEQ ID No. 1 or 2), or shRNA, a decoy nucleic acid that inhibits the promoter activity by binding to the transcription factor of the promoter of the Synoviolin gene or antisense oligonucleotide against gene coding the Synoviolin. The nerve cell differentiation inducing drug of the present invention is used for the treatment of neural disorders including Alzheimer's disease, Parkinson's disease, peripheral nerve disorders or spinal injury.

The invention relates to an induction method for promoting differentiation of human umbilical cord mesenchymal stem cells to osteoblasts, which comprises the following steps of: acquiring umbilical cord tissue blocks, carrying out primary culture on the stem cells, carrying out subculture on the stem cells and induction differentiation of the stem cells to chondrocytes, wherein the induction of the differentiation of the stem cells to the chondrocytes comprises the following steps of: carrying out resuspension subculture on a serum-free culture medium until Pe generation human umbilical cord mesenchymal stem cells are prepared into a Pe generation human umbilical cord mesenchymal stem cell suspension solution; the Pe generation human umbilical cord mesenchymal stem cell suspension solutionis cultured in serum-free medium containing an osteogenic differentiation inducer, the serum-free medium containing the osteogenic differentiation inducer is replaced every three and a half days, after the induction is carried out for 14 days, osteoblasts are obtained; wherein e=6, 7, 8, 9, 10. The method can differentiate human umbilical cord mesenchymal stem cells into osteoblasts, and has great significance in repairing human bone tissues and treating bone injuries.

The invention relates to a method for preparing a human umbilical cord mesenchymal stem cell injection for treating ischemic femoral head necrosis by cavity injection. The method comprises the steps of obtaining an umbilical tissue block, performing primary culture of stem cells, subculturing the stem cells, and preparing the human umbilical cord mesenchymal stem cell injection. The method for preparing the human umbilical cord mesenchymal stem cell injection comprises resuspending the Pe-generation human umbilical cord mesenchymal stem cells with a compound electrolyte injection, and repeatedly purging; after the Pe-generation human umbilical cord mesenchymal stem cell suspension is uniform, supplementing the compound electrolyte injection to adjust the concentration of the human umbilical cord mesenchymal stem cells to 4*10<4-6>*10<4> cells / mL, and adding an osteogenic differentiation inducer, to obtain the human umbilical cord mesenchymal stem cell injection, wherein e is equal to 6, 7, 8, 9, and 10. The human umbilical cord mesenchymal stem cells can be differentiated into osteoblasts, and the method has important significance in repairing human bone formation tissue and treating bone damage.

The invention provides microRNA used for inducing leukemia cell differentiation and application thereof in the induction of erythroid differentiation of tumor cell lines K562. The microRNA not only has the advantages of cheapness, no toxic or side effect, long duration, high transfection efficiency and the like, but also has the characteristics of stronger action and effectiveness of various indexes for tumor cell differentiation compared with a conventional human leukemia cell erythroid differentiation siRNA inducer.

Provided is an agent developed to be capable of alleviating and suppressing muscle atrophy or muscle mass reduction, even for the elderly and even without requiring exercise, by inducing myogenesis. Provided is a composition for treating or preventing disorders or diseases associated with muscle atrophy, or for promoting muscle regeneration, the composition containing, as an active ingredient, a myogenesis inducing agent composed of miR-199 or an DNA that contains an miR-199 gene encoding the miR-199.

The present invention relates to a pharmaceutical composition for the treatment and prevention of cancer and the preparation method thereof, especially to a cell differentiation agent named CDA-II which is prepared by reverse phase chromatography of fresh human urine. The pharmaceutical composition is effective for the treatment and prevention of cancer. The active components in CDA-II contain differentiation inducers, differentiation helper inducers and an anticachexia agent, which act cooperatively to achieve the best therapeutic effect.

A synthetic peptide having a stem cell differentiation-inducing activity to induce differentiation of pluripotent stem cells into endodermal cells, a stem cell differentiation inducer having this peptide as an active ingredient, and a method for inducing differentiation of pluripotent stem cells using these. The synthetic peptide provided by the present invention contains a stem cell differentiation-inducing peptide sequence, and this stem cell differentiation-inducing peptide sequence is selected from an amino acid sequence constituting a signal peptide in any of amyloid precursor proteins (APP), amyloid precursor-like protein (APLP) 1 and APLP2, which are known as proteins belonging to the APP family, a partial amino acid sequence an amino acid sequence constituting this signal peptide, or a modified amino acid sequence formed by substitution, deletion and / or addition of 1, 2 or 3 amino acid residues in these amino acid sequences.

This invention provides a method for administration of an effective amount of RANKL-binding molecules that act on prechondrocytes and / or mesenchymal stem cells, accelerate cartilage differentiation, proliferation, and maturation of such cells, enhance chondrocyte differentiation, and induce chondrocyte proliferation to induce chondrocyte proliferation and differentiation or increase cartilage matrix production and a pharmaceutical composition used for inducing chondrocyte proliferation and differentiation or increasing cartilage matrix production. The pharmaceutical composition used for treatment or prevention of a chondropathies comprises, as an active ingredient, a compound that acts on prechondrocytes and / or mesenchymal stem cells and induces at least one of the following: (a) acceleration of prechondrocyte and / or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and / or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and / or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix.

A novel composition and health food having a good pharmacological activity and which can be readily absorbed through an alimentary canal are provided. The composition induced apoptosis of cells and includes an agaricus extract. The composition may further comprise a pharmaceutically acceptable carrier. Typically, the cells are cancer cells. The composition may further include a differentiation inductionagent. Preferably, the differentiation induction agent is a vitamin A derivative. The vitamin A derivative may be tretinoin. The agaricus extract may include a main fraction eluted chromatographically of a molecular weight of 100 to 2000, which is obtained by the steps of extraction with hot water from a fruiting body of agaricus, dialyzing the extract and performing a,chromatography process on the dialyzate.

The invention discloses an autophagy-based stem cell myocardial cell induced differentiation method and an application thereof. The method comprises the following steps of step 1, preparing an autophagy inducer wherein, the autophagy inducer dissolves in DMSO to prepare mother liquor, the mother liquor is stored at 20 DEG C, a solvent DMSO with the concentration being 0.01% is served as a controlgroup, and the mother liquor is added once when liquor is changed; step 2, stem cell culture; step 3, a first stage for stem cell induction, wherein a myocardial differentiation inducer is added, andcomprises the autophagy inducer prepared in the step 1 and vitamin C; step 4, a second stage for stem cell induction, wherein after good embryoid bodies are obtained through suspension culture, embryoid bodies are transferred into a cell culture plate for adherent culture, the induced culture solution is the same as that in the first stage, the liquor is exchanged each day or every two days according to the cell growth condition, and as time goes on, spontaneous rhythmic jump of the embryoid bodies is observed. The method improves the induced differentiation efficiency and is suitable for popularization and application.